Tests radiation before stem cell transplant in multiple myeloma
Tests radiation with melphalan before stem cell transplant in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Helical Tomotherapy in Multiple Myeloma
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05970198, who can take part
Where in China
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fuling Zhou
- Trial code
- NCT05970198
- Record updated
- 1 August 2023
- Original description
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.Read full original descriptionShow less
A Prospective Randomized Controlled Study of Helical Tomotherapy for Pre-transplantation Pretreatment of Autologous Hematopoietic Stem Cells in Multiple Myeloma
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.
Inclusion: Multiple myeloma patients receiving induction therapy and stem cell mobilization preparation for autologous transplantation; Should agree to comply with all contraceptive requirements; 3, ECOG≤2; Total bilirubin, ALT and AST <2×UNL (upper limit of normal), BUN < 30 mg/dL; 5. At least 2 x 10\^6 CD34+ cells /kg were collected; 6.absolute neutrophil count >1000/uL and a platelet count of >100,000/uL; 7. The expected survival time is more than 3 months; 8. Written informed consent was obtained from the patients or their immediate family members.
Exclusion: According to the investigator's judgment, patients who cannot tolerate melphalan and radiotherapy; Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or seropositive for human immunodeficiency virus (HIV); patients with uncontrolled or severe cardiovascular disease; According to the protocol or the investigator's judgment, the patient has a serious physical or mental illness; Any of the following was an exclusion criterion:.